[Biologic therapy and new therapeutic opportunities in systemic lupus erythematosus].
Systemic lupus erythematosus is a connective tissue disease of unknown origin and unpredictable course. At the moment there is no specific targeted treatment for the disease and corticosteroids are still main therapeutic option. Steroid use, however brings many side effects. Therefore searching for new treatment strategies is at the moment the main challenge for rheumatologists. The potential targets for the treatment include B and T cells co-stimulation molecules and various cytokines. In the paper potential targets for treatment of SLE have been reviewed with the special emphasis to the result of recently finished clinical trials in this indication.
Oddział Chorób Wewnetrznych i Reumatologii SUM SPSK nr 7 GCM w Katowicach. oag@op.pl
Olga
O
Gumkowska
Przemysław J
PJ
Kotyla
Eugeniusz J
EJ
Kucharz
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*
D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D007155:Immunologic Factors; C448700:epratuzumab; C511911:belimumab; D007372:Interferons